Cargando…

Fibroblast growth factor 23, klotho and heparin

Fibroblast growth factor (FGF) 23 is a bone-derived hormone that regulates phosphate and vitamin D metabolism by targeting the kidney. When highly elevated, such as in chronic kidney disease (CKD), FGF23 can also target the heart and induce pathologic remodeling. Here we discuss the mechanisms that...

Descripción completa

Detalles Bibliográficos
Autores principales:	Thomas, S. Madison, Li, Qing, Faul, Christian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	MINERAL METABOLISM: Edited by Aline Martin and Tamara Isakova
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10241433/ https://www.ncbi.nlm.nih.gov/pubmed/37195242 http://dx.doi.org/10.1097/MNH.0000000000000895

Ejemplares similares

Effects of sodium glucose cotransporter 2 inhibitors on mineral metabolism in type 2 diabetes mellitus
por: Vinke, Joanna Sophia J., et al.
Publicado: (2019)

Bone and heart health in chronic kidney disease: role of dentin matrix protein 1
por: Martin, Aline
Publicado: (2019)

Lessons from effect of etelcalcetide on left ventricular hypertrophy in patients with end-stage kidney disease
por: Dörr, Katharina, et al.
Publicado: (2022)

α-Klotho's effects on mineral homeostasis are fibroblast growth factor-23 dependent
por: Erben, Reinhold G.
Publicado: (2018)

Favorable Effects of Burosumab on Fibroblast Growth Factor 23-Related Osteomalacia: A Case Report
por: Oe, Yuki, et al.
Publicado: (2021)

Causal Effect of Fibroblast Growth Factor 23 on Osteoporosis and Cardiometabolic Disorders: A Mendelian Randomization Study
por: Yokomoto-Umakoshi, Maki, et al.
Publicado: (2021)

PSAT173 Weekly Supplementation with Vitamin D3 reduces 1,25(OH)2 vitamin D3 Measured by Mass Spectrometry, and increases Fibroblast-like growth factor 23 (FGF23) in Individuals with and without Primary Hyperparathyroidism (PHPT)
por: Sidana, Shivani, et al.
Publicado: (2022)

SUN-372 Deterioration of Bone Microarchitecture in Prediabetes Is Partly Mediated Through Fibroblast Growth Factor 21
por: Lui, David T W, et al.
Publicado: (2020)

Role of Fibroblast Growth Factor 23 (FGF23) and αKlotho in Cancer
por: Ewendt, Franz, et al.
Publicado: (2021)

FGF23 Actions on Target Tissues—With and Without Klotho
por: Richter, Beatrice, et al.
Publicado: (2018)

Fibroblast growth factor 23—Klotho and hypertension: experimental and clinical mechanisms
por: Freundlich, Michael, et al.
Publicado: (2020)

The Role of Fibroblast Growth Factor 23 in Inflammation and Anemia
por: Czaya, Brian, et al.
Publicado: (2019)

SAT-362 A Bone to Pick with FGF23
por: Soliman, Peter, et al.
Publicado: (2020)

MON-502 It's Not Always Osteoporosis: FGF-23 Induced Osteomalacia
por: Bello Segura, Manuel, et al.
Publicado: (2019)

OR23-06 Long Term Outcomes Of Parathyroid Autografts In Primary Hyperparathyroidism
por: Chuki, Elias, et al.
Publicado: (2023)

Severe Hypophosphatemia and Elevated FGF23 Level Following Zoledronic Acid Infusion
por: Betlachin, Anna, et al.
Publicado: (2021)

Diagnostic Dilemma of Elevated FGF23 in a Patient With Osteomalacia: A Case Report
por: Bulut, Aysegul, et al.
Publicado: (2021)

SAT-385 A Normal FGF23 Does Not Preclude Tumor Induced Osteomalacia (TIO)
por: Nandam, Neeharika, et al.
Publicado: (2020)

MON-LB087 Synthesis of Osteocyte-Derived Phosphaturic Hormone FGF23 via IP3/PKC Signaling Downstream of the Extra-Large Gα Subunit (XLαs)
por: He, Qing, et al.
Publicado: (2019)

THU462 Clinical Features & Management Of FGF23 Secreting Tumors: Series Of 40 Clinical Cases
por: Gronskaia, Sofya, et al.
Publicado: (2023)

OR23-01 The Nonredundant Role Of Beta-Amyloid In Mediating Tonic PTH Secretion In Physiological And Pathological States
por: Tu, Chia-Ling, et al.
Publicado: (2023)

SUN-364 Enthesophytes Are a Common Feature of FGF23-Mediated Hypophosphatemia Due to Tumor-Induced Osteomalacia
por: Gafni, Rachel Ilana, et al.
Publicado: (2020)

SUN-345 Use of Anti-FGF23 Monoclonal Antibody in the Treatment of Children and Adolescents with X-Linked Hypophosphatemic Rickets
por: Cassinelli, Hamilton Raul, et al.
Publicado: (2020)

Changes in Fibroblast Growth Factor 23 and Soluble Klotho Levels After Hemodialysis Initiation
por: Kawabata, Chiaki, et al.
Publicado: (2019)

SUN-LB093 Change in Bone Mineral Density over One Year Was Not Associated with FGF-23 in Patients New to Dialysis
por: Roy, Neil, et al.
Publicado: (2019)

SUN-359 Antenatal Oral Iron Supplementation, FGF23 and Bone Metabolism in Kenyan Women and Their Offspring: A Randomised Controlled Trial
por: Braithwaite, Vickie S, et al.
Publicado: (2020)

Circulating MicroRNA-23a-5p Is a Potential Biomarker for Recovery of Bone Mass After Parathyroidectomy in Primary Hyperparathyroidism
por: Lee, Seunghyun, et al.
Publicado: (2021)

THU393 An Internal NPT2A Cryptic PDZ Motif Is A Novel Regulator of PTH- And FGF23-sensitive Phosphate Transport
por: Sneddon, Bruce W, et al.
Publicado: (2023)

OR29-01 Long-Term Safety in Adults with X-Linked Hypophosphatemia (XLH) Treated with Burosumab, a Fully Human Monoclonal Antibody Against FGF23: Final Results of a Phase 3 Trial
por: Perwad, Farzana, et al.
Publicado: (2020)

SAT-LB085 First Report of Burosumab (Anti-FGF23 Monoclonal Antibody) for Rickets Complicating HRAS-Associated Cutaneous Skeletal Hypophosphatemia Syndrome
por: Smith, Pamela, et al.
Publicado: (2019)

OR23-04 Treatment Of Chronic Hypoparathyroidism With Eneboparatide (AZP-3601), A Novel PTH 1 Receptor Agonist: Results From A Phase 2 Trial
por: Kamenicky, Peter, et al.
Publicado: (2023)

OR23-02 Genotype-Phenotype Correlation In Calcium Sensing Receptor (Casr) Gene Gain-Of-Function Mutations: A Case Series And Report Of 2 Novel Mutations
por: Ali, Dalal S, et al.
Publicado: (2023)

OR23-05 Log-term Efficacy And Safety Of Transcon PTH In Adults With Hypoparathyroidism: 52-week Results From The Open-label Extension Of The Phase 3 Pathway Trial
por: Clarke, Bart, et al.
Publicado: (2023)

Tumor-Induced Osteomalacia With Normal Fibroblast Growth Factor-23 (FGF23) and Idiopathic Hypercalciuria
por: Velazquez-Navarro, Jassel A, et al.
Publicado: (2022)

FRI671 Association Of Insulin-like Growth Factor-1 (igf-1) With Bone Mineral Density (bmd) In Survivors Of Childhood Acute Leukemia 
por: Kim, Seulki, et al.
Publicado: (2023)

Significant roles of anti-aging protein klotho and fibroblast growth factor23 in cardiovascular disease
por: Ding, Hong-Ying, et al.
Publicado: (2015)

Clinical Potential of Targeting Fibroblast Growth Factor‐23 and αKlotho in the Treatment of Uremic Cardiomyopathy
por: Law, Jonathan P., et al.
Publicado: (2020)

Fibroblast Growth Factor-23-Klotho Axis in Cardiorenal Syndrome: Mediators and Potential Therapeutic Targets
por: Navarro-García, José Alberto, et al.
Publicado: (2021)

OR23-03 Sustained Normalization Of Mineral Homeostasis In Autosomal Dominant Hypocalcemia Type 1: Results From A Phase 2 Study Over 18 Months Of Encaleret (CLTX-305) Treatment (NCT04581629)
por: Ilana Gafni, Rachel, et al.
Publicado: (2023)

SAT190 The Effect Of Mechanical Loading On Bone Growth Ex Vivo
por: Aeppli, Tim, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_h64ak6br9f20m4490ure57vk6r